The clinical implications of the prostate cancer prevention trial.
Marberger
M
M
Department of Urology, University of Vienna Medical School, Vienna, Austria.
Adolfsson
J
J
Borkowski
A
A
Fitzpatrick
J
J
Kirk
D
D
Prezioso
D
D
Rabaça
C
C
Solsona
E
E
Teillac
P
P
D000368:Aged; D003951:Diagnostic Errors; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D018120:Finasteride; D017430:Prostate-Specific Antigen